Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
primary care clinic
Be at least 18 years of age
Have a confirmed diagnosis of MM
Starting lenalidomide treatment for MM (due to relapsed or refractory disease) after one prior treatment.
Have personally signed and dated a legally effective written informed consent form prior to admission to the study.
Must be willing and able to understand and comply with the study requirements.
Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening.
Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.